Host-pathogen interactions and immune evasion strategies in Francisella tularensis pathogenicity

Infection and Drug Resistance

Volumn 7, Issue , 2014, Pages 239-251

  Steiner, Don J ^a   Furuya, Yoichi ^a   Metzger, Dennis W ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Francisella tularensis; Host immunity; LVS; Schu S4; Tularemia

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 17; TULAREMIA VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; CELLULAR IMMUNITY; CYTOKINE RESPONSE; FRANCISELLA TULARENSIS; HOST PATHOGEN INTERACTION; HUMAN; HUMORAL IMMUNITY; IMMUNE EVASION; IMMUNIZATION; IMMUNOMODULATION; INNATE IMMUNITY; MACROPHAGE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PATHOGENICITY ISLAND; PNEUMONIA; REVIEW; SKIN INFECTION; TULAREMIA;

EID: 84907881358     PISSN: None     EISSN: 11786973     Source Type: Journal    
DOI: 10.2147/IDR.S53700     Document Type: Review

References (143)

1. McCoy G. A plague-like disease of rodents. Public Health Bulletin. 1911;43:53-72.
2. Wherry WB, Lamb BH. Infection of man with Bacterium tularense. J Infect Dis. 1914;189(7):1321-1329.
3. McCrumb F Jr, Snyder MJ, Woodward TE. Studies on human infection with Pasteurella tularensis: comparison of streptomycin and chloramphenicol in the prophylaxis of clinical disease. Trans Assoc Am Physicians. 1957;70:74-79; discussion 79-80.
4. McCoy G., Chapin CW. Further observations on a plague-like disease of rodents with a preliminary note on the causative agent, Bacterium tularense. J Infect Dis. 1912;10(1):61-72.
5. Hesselbrock W, Foshay L. The morphology of Bacterium tularense. J Bacteriol. 1945;49(3):209-231.
6. Ellis J, Oyston PC, Green M, Titball RW. Tularemia. Clin Microbiol Rev. 2002;15(4):631-646.
7. Titball R., Johansson A, Forsman M. Will the enigma of Francisella tularensis virulence soon be solved? Trends Microbiol. 2003;11(3):118-123.
8. McLendon MK, Apicella MA, Allen LA. Francisella tularensis: taxonomy, genetics, and immunopathogenesis of a potential agent of biowarfare. Annu Rev Microbiol. 2006;60:167-185.
9. Goethert HK, Telford SR. Differential mortality of dog tick vectors due to infection by diverse Francisella tularensis tularensis genotypes. Vector Borne Zoonotic Dis. 2011;11(9):1263-1268.
10. McCrumb FR. Aerosol infection of man with Pasteurella tularensis. Bacteriol Rev. 1961;25(3):262-267.
11. Cox CS. Aerosol survival of Pasteurella tularensis disseminated from the wet and dry states. Appl Microbiol. 1971;21(3):482-486.
12. Harris S. Japanese biological warfare research on humans: a case study of microbiology and ethics. Ann N Y Acad Sci. 1992;666:21-52.
13. Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA. 2001;285(21):2763-2773.
14. Oyston PC, Sjöstedt A, Titball RW. Tularaemia: bioterrorism defence renews interest in Francisella tularensis. Nat Rev Microbiol. 2004;2(12):967-978.
15. Eigelsbach HT, Downs CM. Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J Immunol. 1961;87:415-425.
16. Tigertt WD. Soviet viable Pasteurella tularensis vaccines. A review of selected articles. Bacteriol Rev. 1962;26:354-373.
17. Salomonsson E, Kuoppa K, Forslund AL, et al. Reintroduction of two deleted virulence loci restores full virulence to the live vaccine strain of Francisella tularensis. Infect Immun. 2009;77(8):3424-3431.
18. Nano FE, Schmerk C. The Francisella pathogenicity island. Ann N Y Acad Sci. 2007;1105:122-137.
19. Nano FE, Zhang N, Cowley SC, et al. A Francisella tularensis pathogenicity island required for intramacrophage growth. J Bacteriol. 2004;186(19):6430-6436.
20. Chou AY, Kennett NJ, Nix EB, Schmerk C., Nano FE, Elkins KL. Generation of protection against Francisella novicida in mice depends on the pathogenicity protein pdpA, but not pdpC or pdpD. Microbes Infect. 2013;15(12):816-827.
21. de Bruin OM, Duplantis BN, Ludu JS, et al. The biochemical properties of the Francisella pathogenicity island (FPI)-encoded proteins IglA, IglB, IglC, pdpB and dotU suggest roles in type VI secretion. Microbiology. 2011;157(Pt 12):3483-3491.
22. Broms JE, Meyer L, Lavander M, Larsson P, Sjöstedt A. DotU and vgrG, core components of type VI secretion systems, are essential for Francisella LVS pathogenicity. PLoS One. 2012;7(4):e34639.
23. Barker JR, Chong A, Wehrly TD, et al. The Francisella tularensis pathogenicity island encodes a secretion system that is required for phagosome escape and virulence. Mol Microbiol. 2009;74(6):1459-1470.
24. Santic M, Molmeret M, Klose KE, Jones S, Kwaik YA. The Francisella tularensis pathogenicity island protein IglC and its regulator MglA are essential for modulating phagosome biogenesis and subsequent bacterial escape into the cytoplasm. Cell Microbiol. 2005;7(7):969-979.
25. Dai S, Mohapatra NP, Schlesinger LS, Gunn JS. Regulation of Francisella tularensis virulence. Front Microbiol. 2010;1:144.
26. Woolard MD, Barrigan LM, Fuller JR, et al. Identification of Francisella novicida mutants that fail to induce prostaglandin E(2) synthesis by infected macrophages. Front Microbiol. 2013;4:16.
27. Broms JE, Meyer L, Sun K, Lavander M, Sjöstedt A. Unique substrates secreted by the type VI secretion system of Francisella tularensis during intramacrophage infection. PLoS One. 2012;7(11):e50473.
28. Smulevich G, Jakopitsch C, Droghetti E, Obinger C. Probing the structure and bifunctionality of catalase-peroxidase (KatG). J Inorg Biochem. 2006;100(4):568-585.
29. Lindgren H, Shen H, Zingmark C, Golovliov I, Conlan W, Sjöstedt A. Resistance of Francisella tularensis strains against reactive nitrogen and oxygen species with special reference to the role of KatG. Infect Immun. 2007;75(3):1303-1309.
30. Bakshi CS, Malik M, Regan K, et al. Superoxide dismutase B gene (sodB)-deficient mutants of Francisella tularensis demonstrate hypersensitivity to oxidative stress and attenuated virulence. J Bacteriol. 2006;188(17):6443-6448.
31. Melillo AA, Mahawar M, Sellati TJ, et al. Identification of Francisella tularensis live vaccine strain CuZn superoxide dismutase as critical for resistance to extracellularly generated reactive oxygen species. J Bacteriol. 2009;191(20):6447-6456.
32. Buddingh GJ, Womack FC. Observations on the infection of chick embryos with Bacterium tularense, brucella, and Pasteurella pestis. J Exp Med. 1941;74(3):213-222.
33. Shepard CC. Nonacid-fast bacteria and HeLa cells: their uptake and subsequent intracellular growth. J Bacteriol. 1959;77(6):701-714.
34. Fortier AH, Leiby DA, Narayanan RB, et al. Growth of Francisella tularensis LVS in macrophages: the acidic intracellular compartment provides essential iron required for growth. Infect Immun. 1995;63(4): 1478-1483.
35. Clemens DL, Lee BY, Horwitz MA. Francisella tularensis enters macrophages via a novel process involving pseudopod loops. Infect Immun. 2005;73(9):5892-5902.
36. Clemens DL, Horwitz MA. Uptake and intracellular fate of Francisella tularensis in human macrophages. Ann N Y Acad Sci. 2007;1105:160-186.
37. Pierini LM. Uptake of serum-opsonized Francisella tularensis by macrophages can be mediated by class A scavenger receptors. Cell Microbiol. 2006;8(8):1361-1370.
38. Balagopal A, MacFarlane AS, Mohapatra N, Soni S, Gunn JS, Schlesinger LS. Characterization of the receptor-ligand pathways important for entry and survival of Francisella tularensis in human macrophages. Infect Immun. 2006;74(9):5114-5125.
39. Schulert GS, Allen LA. Differential infection of mononuclear phagocytes by Francisella tularensis: role of the macrophage mannose receptor. J Leukoc Biol. 2006;80(3):563-571.
40. Geier H, Celli J. Phagocytic receptors dictate phagosomal escape and intracellular proliferation of Francisella tularensis. Infect Immun. 2011;79(6):2204-2214.
41. Clemens DL, Lee BY, Horwitz MA. Virulent and avirulent strains of Francisella tularensis prevent acidification and maturation of their phagosomes and escape into the cytoplasm in human macrophages. Infect Immun. 2004;72(6):3204-3217.
42. Sjöstedt A. Intracellular survival mechanisms of Francisella tularensis, a stealth pathogen. Microbes Infect. 2006;8(2):561-567.
43. Asare R, Abu Kwaik Y. Molecular complexity orchestrates modulation of phagosome biogenesis and escape to the cytosol of macrophages by Francisella tularensis. Environ Microbiol. 2010;12(9):2559-2586.
44. Checroun C, Wehrly TD, Fischer ER, Hayes SF, Celli J. Autophagy-mediated reentry of Francisella tularensis into the endocytic compartment after cytoplasmic replication. Proc Natl Acad Sci U S A. 2006;103(39):14578-14583.
45. Steele S, Brunton J, Ziehr B, Taft-Benz S, Moorman N, Kawula T. Francisella tularensis harvests nutrients derived via ATG5-independent autophagy to support intracellular growth. PLoS Pathog. 2013;9(8): e1003562.
46. Lai XH, Golovliov I, Sjöstedt A. Francisella tularensis induces cytopathogenicity and apoptosis in murine macrophages via a mechanism that requires intracellular bacterial multiplication. Infect Immun. 2001;69(7):4691-4694.
47. Hall JD, Craven RR, Fuller JR, Pickles RJ, Kawula TH. Francisella tularensis replicates within alveolar type II epithelial cells in vitro and in vivo following inhalation. Infect Immun. 2007;75(2):1034-1039.
48. Hall JD, Woolard MD, Gunn BM, et al. Infected-host-cell repertoire and cellular response in the lung following inhalation of Francisella tularensis Schu S4, LVS, or U112. Infect Immun. 2008;76(12):5843-5852.
49. Horzempa J, O’Dee DM, Shanks RM, Nau GJ. Francisella tularensis DeltapyrF mutants show that replication in nonmacrophages is sufficient for pathogenesis in vivo. Infect Immun. 2010;78(6):2607-2619.
50. Forestal CA, Malik M, Catlett SV, et al. Francisella tularensis has a significant extracellular phase in infected mice. J Infect Dis. 2007;196(1):134-137.
51. Yu JJ, Raulie EK, Murthy AK, Guentzel MN, Klose KE, Arulanandam BP. The presence of infectious extracellular Francisella tularensis subsp. novicida in murine plasma after pulmonary challenge. Eur J Clin Microbiol Infect Dis. 2008;27(4):323-325.
52. Lindgren H, Honn M, Golovlev I, Kadzhaev K, Conlan W, Sjöstedt A. The 58-kilodalton major virulence factor of Francisella tularensis is required for efficient utilization of iron. Infect Immun. 2009;77(10):4429-4436.
53. Olakanmi O, Gunn JS, Su S, Soni S, Hassett DJ, Britigan BE. Gallium disrupts iron uptake by intracellular and extracellular Francisella strains and exhibits therapeutic efficacy in a murine pulmonary infection model. Antimicrob Agents Chemother. 2010;54(1):244-253.
54. Hazlett KR, Caldon SD, McArthur DG, et al. Adaptation of Francisella tularensis to the mammalian environment is governed by cues which can be mimicked in vitro. Infect Immun. 2008;76(10):4479-4488.
55. Pan X, Tamilselvam B, Hansen EJ, Daefler S. Modulation of iron homeostasis in macrophages by bacterial intracellular pathogens. BMC Microbiol. 2010;10:64.
56. Lindgren H, Honn M, Salomonsson E, Kuoppa K, Forsberg A, Sjöstedt A. Iron content differs between Francisella tularensis subspecies tularensis and subspecies holarctica strains and correlates to their susceptibility to H(2)O(2)-induced killing. Infect Immun. 2011;79(3):1218-1224.
57. Councilman W, Strong R. Plague-like infections in rodents. Trans Assoc Am Phys. 1921;36:135-143.
58. Chiavolini D, Alroy J, King CA, et al. Identification of immunologic and pathologic parameters of death versus survival in respiratory tularemia. Infect Immun. 2008;76(2):486-496.
59. Foshay L, Hesselbrock WH, Wittenberg HJ, Rodenberg AH. Vaccine prophylaxis against tularemia in man. Am J Public Health Nations Health. 1942;32(10):1131-1145.
60. Foshay L. A comparative study of the treatment of tularemia with immune serum, hyperimmune serum and streptomycin. Am J Med. 1946;1:180-188.
61. Conlan JW, North RJ. Early pathogenesis of infection in the liver with the facultative intracellular bacteria Listeria monocytogenes, Francisella tularensis, and Salmonella typhimurium involves lysis of infected hepatocytes by leukocytes. Infect Immun. 1992;60(12):5164-5171.
62. Conlan JW, KuoLee R, Shen H, Webb A. Different host defences are required to protect mice from primary systemic vs pulmonary infection with the facultative intracellular bacterial pathogen, Francisella tularensis LVS. Microb Pathog. 2002;32(3):127-134.
63. Anthony LD, Burke RD, Nano FE. Growth of Francisella spp. in rodent macrophages. Infect Immun. 1991;59(9):3291-3296.
64. Fortier AH, Polsinelli T, Green SJ, Nacy CA. Activation of macrophages for destruction of Francisella tularensis: identification of cytokines, effector cells, and effector molecules. Infect Immun. 1992;60(3): 817-825.
65. Bar-Haim E, Gat O, Markel G, Cohen H, Shafferman A, Velan B. Interrelationship between dendritic cell trafficking and Francisella tularensis dissemination following airway infection. PLoS Pathog. 2008;4(11):e1000211.
66. Mares CA, Ojeda SS, Morris EG, Li Q, Teale JM. Initial delay in the immune response to Francisella tularensis is followed by hypercytokinemia characteristic of severe sepsis and correlating with upregulation and release of damage-associated molecular patterns. Infect Immun. 2008;76(7):3001-3010.
67. Sharma J, Li Q, Mishra BB, Pena C, Teale JM. Lethal pulmonary infection with Francisella novicida is associated with severe sepsis. J Leukoc Biol. 2009;86(3):491-504.
68. Cowley SC. Editorial: proinflammatory cytokines in pneumonic tularemia: too much too late? J Leukoc Biol. 2009;86(3):469-470.
69. Sharma J, Mares CA, Li Q, Morris EG, Teale JM. Features of sepsis caused by pulmonary infection with Francisella tularensis type A strain. Microb Pathog. 2011;51(1-2):39-47.
70. Mares CA, Sharma J, Li Q, et al. Defect in efferocytosis leads to alternative activation of macrophages in Francisella infections. Immunol Cell Biol. 2011;89(2):167-172.
71. Malik M, Bakshi CS, McCabe K, et al. Matrix metalloproteinase 9 activity enhances host susceptibility to pulmonary infection with type A and B strains of Francisella tularensis. J Immunol. 2007;178(2): 1013-1020.
72. Schwartz JT, Barker JH, Kaufman J, Fayram DC, McCracken JM, Allen LA. Francisella tularensis inhibits the intrinsic and extrinsic pathways to delay constitutive apoptosis and prolong human neutrophil lifespan. J Immunol. 2012;188(7):3351-3363.
73. Stenmark S, Sunnemark D, Bucht A, Sjöstedt A. Rapid local expression of interleukin-12, tumor necrosis factor alpha, and gamma interferon after cutaneous Francisella tularensis infection in tularemia-immune mice. Infect Immun. 1999;67(4):1789-1797.
74. Elkins KL, Cooper A, Colombini SM, Cowley SC, Kieffer TL. In vivo clearance of an intracellular bacterium, Francisella tularensis LVS, is dependent on the p40 subunit of interleukin-12 (IL-12) but not on IL-12 p70. Infect Immun. 2002;70(4):1936-1948.
75. Slight SR, Lin Y, Messmer M, Khader SA. Francisella tularensis LVS-induced Interleukin-12 p40 cytokine production mediates dendritic cell migration through IL-12 receptor beta1. Cytokine. 2011;55(3):372-379.
76. Lopez MC, Duckett NS, Baron SD, Metzger DW. Early activation of NK cells after lung infection with the intracellular bacterium, Francisella tularensis LVS. Cell Immunol. 2004;232(1-2):75-85.
77. Furuya Y, Kirimanjeswara G., Roberts S, Metzger DW. Increased susceptibility of IgA-deficient mice to pulmonary Francisella tularensis live vaccine strain infection. Infect Immun. 2013;81(9):3434-3441.
78. Baron SD, Singh R, Metzger DW. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion. Infect Immun. 2007;75(5):2152-2162.
79. Elkins KL, Colombini SM, Krieg AM, De Pascalis R. NK cells activated in vivo by bacterial DNA control the intracellular growth of Francisella tularensis LVS. Microbes Infect. Jan 2009;11(1):49-56.
80. Chen W, KuoLee R, Shen H, Conlan JW. Susceptibility of immunodeficient mice to aerosol and systemic infection with virulent strains of Francisella tularensis. Microb Pathog. 2004;36(6):311-318.
81. Duckett NS, Olmos S, Durrant DM, Metzger DW. Intranasal interleukin-12 treatment for protection against respiratory infection with the Francisella tularensis live vaccine strain. Infect Immun. 2005;73(4): 2306-2311.
82. Polsinelli T, Meltzer MS, Fortier AH. Nitric oxide-independent killing of Francisella tularensis by IFN-gamma-stimulated murine alveolar macrophages. J Immunol. 1994;153(3):1238-1245.
83. Lindgren H, Stenman L, Tarnvik A, Sjöstedt A. The contribution of reactive nitrogen and oxygen species to the killing of Francisella tularensis LVS by murine macrophages. Microbes Infect. 2005;7(3): 467-475.
84. Sjöstedt A, North RJ, Conlan JW. The requirement of tumour necrosis factor-alpha and interferon-gamma for the expression of protective immunity to secondary murine tularaemia depends on the size of the challenge inoculum. Microbiology. 1996;142(Pt 6):1369-1374.
85. Henry T, Brotcke A, Weiss DS, Thompson LJ, Monack DM. Type I interferon signaling is required for activation of the inflammasome during Francisella infection. J Exp Med. 2007;204(5):987-994.
86. Cole LE, Santiago A, Barry E, et al. Macrophage proinflammatory response to Francisella tularensis live vaccine strain requires coordination of multiple signaling pathways. J Immunol. 2008;180(10): 6885-6891.
87. Abplanalp AL, Morris IR, Parida BK, Teale JM, Berton MT. TLR-dependent control of Francisella tularensis infection and host inflammatory responses. PLoS One. 2009;4(11):e7920.
88. Edwards JA, Rockx-Brouwer D, Nair V, Celli J. Restricted cytosolic growth of Francisella tularensis subsp. tularensis by IFN-gamma activation of macrophages. Microbiology. 2010;156(Pt 2):327-339.
89. Sjöstedt A, Conlan JW, North RJ. Neutrophils are critical for host defense against primary infection with the facultative intracellular bacterium Francisella tularensis in mice and participate in defense against reinfection. Infect Immun. 1994;62(7):2779-2783.
90. KuoLee R, Harris G, Conlan JW, Chen W. Role of neutrophils and NADPH phagocyte oxidase in host defense against respiratory infection with virulent Francisella tularensis in mice. Microbes Infect. 2011;13(5):447-456.
91. Metzger DW, Salmon SL, Kirimanjeswara G. Differing effects of IL-10 in cutaneous and pulmonary Francisella tularensis LVS infection. Infect Immun. 2013;81(6):2022-2027.
92. Gentry M, Taormina J, Pyles RB, et al. Role of primary human alveolar epithelial cells in host defense against Francisella tularensis infection. Infect Immun. 2007;75(8):3969-3978.
93. Ketavarapu JM, Rodriguez AR, Yu JJ, et al. Mast cells inhibit intramacrophage Francisella tularensis replication via contact and secreted products including IL-4. Proc Natl Acad Sci U S A. 2008;105(27):9313-9318.
94. Rodriguez AR, Yu JJ, Guentzel MN, et al. Mast cell TLR2 signaling is crucial for effective killing of Francisella tularensis. J Immunol. 2012;188(11):5604-5611.
95. Eigelsbach HT, Hunter DH, Janssen WA, Dangerfield HG, Rabinowitz SG. Murine model for study of cell-mediated immunity: protection against death from fully virulent Francisella tularensis infection. Infect Immun. 1975;12(5):999-1005.
96. Fortier AH, Slayter MV, Ziemba R, Meltzer MS, Nacy CA. Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect Immun. 1991;59(9):2922-2928.
97. Sjöstedt A, Sandstrom G, Tarnvik A. Humoral and cell-mediated immunity in mice to a 17-kilodalton lipoprotein of Francisella tularensis expressed by Salmonella typhimurium. Infect Immun. 1992;60(7):2855-2862.
98. Golovliov I, Ericsson M, Akerblom L, Sandstrom G, Tarnvik A, Sjöstedt A. Adjuvanticity of ISCOMs incorporating a T cell-reactive lipoprotein of the facultative intracellular pathogen Francisella tularensis. Vaccine. 1995;13(3):261-267.
99. Anderson RV, Crane DD, Bosio CM. Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organs. Vaccine. 2010;28(40):6562-6572.
100. Markel G, Bar-Haim E, Zahavy E, et al. The involvement of IL-17A in the murine response to sub-lethal inhalational infection with Francisella tularensis. PLoS One. 2010;5(6):e11176.
101. Melillo AA, Foreman O, Bosio CM, Elkins KL. T-bet regulates immunity to F. tularensis LVS infection, particularly in lungs. Infect Immun. 2014;82(4):1477-1490.
102. Cowley SC, Sedgwick JD, Elkins KL. Differential requirements by CD4+ and CD8+ T cells for soluble and membrane TNF in control of Francisella tularensis live vaccine strain intramacrophage growth. J Immunol. 2007;179(11):7709-7719.
103. Lin Y, Ritchea S, Logar A, et al. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity. 2009;31(5):799-810.
104. Cowley SC, Elkins KL. Multiple T cell subsets control Francisella tularensis LVS intracellular growth without stimulation through macrophage interferon gamma receptors. J Exp Med. 2003;198(3):379-389.
105. Cowley SC, Hamilton E, Frelinger JA, Su J, Forman J, Elkins KL. CD4-CD8-T cells control intracellular bacterial infections both in vitro and in vivo. J Exp Med. 2005;202(2):309-319.
106. Cowley SC, Meierovics AI, Frelinger JA, Iwakura Y, Elkins KL. Lung CD4-CD8-double-negative T cells are prominent producers of IL-17A and IFN-gamma during primary respiratory murine infection with Francisella tularensis live vaccine strain. J Immunol. 2010;184(10): 5791-5801.
107. Rhinehart-Jones TR, Fortier AH, Elkins KL. Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells. Infect Immun. 1994;62(8): 3129-3137.
108. Fulop M, Mastroeni P, Green M, Titball RW. Role of antibody to lipopolysaccharide in protection against low-and high-virulence strains of Francisella tularensis. Vaccine. 2001;19(31):4465-4472.
109. Sebastian S, Pinkham JT, Lynch JG, et al. Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis. Vaccine. 2009;27(4):597-605.
110. Mara-Koosham G, Hutt JA, Lyons CR, Wu TH. Antibodies contribute to effective vaccination against respiratory infection by type A Francisella tularensis strains. Infect Immun. 2011;79(4):1770-1778.
111. Porsch-Ozcurumez M, Kischel N, Priebe H, Splettstosser W, Finke EJ, Grunow R. Comparison of enzyme-linked immunosorbent assay, Western blotting, microagglutination, indirect immunofluorescence assay, and flow cytometry for serological diagnosis of tularemia. Clin Diagn Lab Immunol. 2004;11(6):1008-1015.
112. Conlan J, Oyston PC. Vaccines against Francisella tularensis. Ann N Y Acad Sci. 2007;1105:325-350.
113. Cowley SC, Elkins KL. Immunity to Francisella. Front Microbiol. 2011;2:26.
114. Thorpe BD, Marcus S. Phagocytosis and intracellular fate of Pasteurella tularensis. 3. In vivo studies with passively transferred cells and sera. J Immunol. 1965;94:578-585.
115. Elkins KL, Rhinehart-Jones T, Nacy CA, Winegar RK, Fortier AH. T-cell-independent resistance to infection and generation of immunity to Francisella tularensis. Infect Immun. 1993;61(3):823-829.
116. Kirimanjeswara G., Golden JM, Bakshi CS, Metzger DW. Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J Immunol. 2007;179(1):532-539.
117. Hajjar AM, Harvey MD, Shaffer SA, et al. Lack of in vitro and in vivo recognition of Francisella tularensis subspecies lipopolysaccharide by Toll-like receptors. Infect Immun. 2006;74(12):6730-6738.
118. Twine SM, Petit MD, Shen H, Mykytczuk NC, Kelly JF, Conlan JW. Immunoproteomic analysis of the murine antibody response to successful and failed immunization with live anti-Francisella vaccines. Biochem Biophys Res Commun. 2006;346(3):999-1008.
119. Asare R, Kwaik YA. Exploitation of host cell biology and evasion of immunity by Francisella tularensis. Front Microbiol. 2010;1:145.
120. Fulop M, Manchee R, Titball R. Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia. Vaccine. 1995;13(13):1220-1225.
121. Conlan JW, Shen H, Webb A, Perry MB. Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen. Vaccine. 2002;20(29-30):3465-3471.
122. Ancuta P, Pedron T, Girard R, Sandstrom G, Chaby R. Inability of the Francisella tularensis lipopolysaccharide to mimic or to antagonize the induction of cell activation by endotoxins. Infect Immun. 1996;64(6): 2041-2046.
123. Okan NA, Kasper DL. The atypical lipopolysaccharide of Francisella. Carbohydr Res. 2013;378:79-83.
124. Vinogradov E, Perry MB, Conlan JW. Structural analysis of Francisella tularensis lipopolysaccharide. Eur J Biochem. 2002; 269(24):6112-6118.
125. Zarrella TM, Singh A, Bitsaktsis C, et al. Host-adaptation of Francisella tularensis alters the bacterium’s surface-carbohydrates to hinder effectors of innate and adaptive immunity. PLoS One. 2011 2011;6(7):e22335.
126. Telepnev M, Golovliov I, Grundstrom T, Tarnvik A, Sjöstedt A. Francisella tularensis inhibits Toll-like receptor-mediated activation of intracellular signalling and secretion of TNF-alpha and IL-1 from murine macrophages. Cell Microbiol. 2003;5(1):41-51.
127. Bosio CM, Dow SW. Francisella tularensis induces aberrant activation of pulmonary dendritic cells. J Immunol. 2005;175(10):6792-6801.
128. Bosio CM, Bielefeldt-Ohmann H, Belisle JT. Active suppression of the pulmonary immune response by Francisella tularensis Schu4. J Immunol. 2007;178(7):4538-4547.
129. Telepnev M, Golovliov I, Sjöstedt A. Francisella tularensis LVS initially activates but subsequently down-regulates intracellular signaling and cytokine secretion in mouse monocytic and human peripheral blood mononuclear cells. Microb Pathog. 2005;38(5-6): 239-247.
130. Golovliov I, Ericsson M, Sandstrom G, Tarnvik A, Sjöstedt A. Identification of proteins of Francisella tularensis induced during growth in macrophages and cloning of the gene encoding a prominently induced 23-kilodalton protein. Infect Immun. 1997;65(6): 2183-2189.
131. Shirey KA, Cole LE, Keegan AD, Vogel SN. Francisella tularensis live vaccine strain induces macrophage alternative activation as a survival mechanism. J Immunol. 2008;181(6):4159-4167.
132. Woolard MD, Wilson JE, Hensley LL, et al. Francisella tularensis-infected macrophages release prostaglandin E2 that blocks T cell proliferation and promotes a Th2-like response. J Immunol. 2007;178(4):2065-2074.
133. Woolard MD, Hensley LL, Kawula T., Frelinger JA. Respiratory Francisella tularensis live vaccine strain infection induces Th17 cells and prostaglandin E2, which inhibits generation of gamma interferon-positive T cells. Infect Immun. 2008;76(6):2651-2659.
134. Wilson JE, Katkere B, Drake JR. Francisella tularensis induces ubiquitin-dependent major histocompatibility complex class II degradation in activated macrophages. Infect Immun. 2009;77(11):4953-4965.
135. Hunt D, Wilson JE, Weih KA, et al. Francisella tularensis elicits IL-10 via a PGE(2)-inducible factor, to drive macrophage MARCH1 expression and class II down-regulation. PLoS One. 2012;7(5):e37330.
136. Chase JC, Celli J, Bosio CM. Direct and indirect impairment of human dendritic cell function by virulent Francisella tularensis Schu S4. Infect Immun. 2009;77(1):180-195.
137. McCaffrey RL, Allen LA. Francisella tularensis LVS evades killing by human neutrophils via inhibition of the respiratory burst and phagosome escape. J Leukoc Biol. 2006;80(6):1224-1230.
138. Brotcke A, Monack DM. Identification of fevR, a novel regulator of virulence gene expression in Francisella novicida. Infect Immun. 2008;76(8):3473-3480.
139. McCaffrey RL, Schwartz JT, Lindemann SR, et al. Multiple mechanisms of NADPH oxidase inhibition by type A and type B Francisella tularensis. J Leukoc Biol. 2010;88(4):791-805.
140. Roth KM, Gunn JS, Lafuse W, Satoskar AR. Francisella inhibits STAT1-mediated signaling in macrophages and prevents activation of antigen-specific T cells. Int Immunol. 2009;21(1):19-28.
141. Nallaparaju KC, Yu JJ, Rodriguez SA, et al. Evasion of IFN-gamma signaling by Francisella novicida is dependent upon Francisella outer membrane protein C. PLoS One. 2011;6(3):e18201.
142. Ireland R, Wang R, Alinger JB, Small P, Bosio CM. Francisella tularensis Schu S4 and Schu S4 lipids inhibit IL-12p40 in primary human dendritic cells by inhibition of IRF1 and IRF8. J Immunol. 2013;191(3):1276-1286.
143. Loegering DJ, Drake JR, Banas JA, et al. Francisella tularensis LVS grown in macrophages has reduced ability to stimulate the secretion of inflammatory cytokines by macrophages in vitro. Microb Pathog. 2006;41(6):218-225.